Estrella Immunopharma, Inc. (NasdaqCM: ESLA)
Health Care · Biotechnology · US
$0.43
+4.88% today · -78.4% 1Y
Estrella Immunopharma, Inc. (NasdaqCM: ESLA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $18.70M and employs 3 people.
Over the last twelve months the share price has lost 78.4%, trading between 0.30 and 3.15.
Tweenvest scores Estrella Immunopharma, Inc. across four factors: quality 22/100, value 32/100. Its strongest factor is value.
ESLA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $18.70M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.25
- Dividend yield
- —
- Beta (5Y)
- 0.93
- 52-week high
- $3.15
- 52-week low
- $0.30
- Avg volume (3M)
- —
- Shares outstanding
- 43.50M
- Employees
- 3
- Next earnings
- —
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
- ISIN
- US2975841048
- Founded
- 2006
- Listed since
- Sep 14, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| HST Global, Inc.OTCPK: HSTC | $18.91M | $0.13 | -80.90% |
| Dextech Medical ABXSAT: DEX | $18.89M | Skr— | — |
| General Biologicals CorporationTPEX: 4117 | $18.79M | NT$8.61 | -8.31% |
| Quoin Pharmaceuticals, Ltd.NasdaqCM: QNRX | $18.74M | $3.90 | -13.33% |
| Akari Therapeutics, PlcNasdaqCM: AKTX | $18.69M | $8.18 | -6.73% |
| Kyntra Bio, Inc.NasdaqGS: KYNB | $18.55M | $4.58 | -12.26% |
| Defence Therapeutics Inc.CNSX: DTC | $18.22M | CA$0.34 | -15.00% |
| Neuphoria Therapeutics Inc.NasdaqGM: NEUP | $17.86M | $3.30 | -1.79% |
Figures last refreshed Oct 18, 2026.